Tipifarnib

Generic Name: Tipifarnib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₂Cl_₂N_₄O

CAS Number: 192185-72-1

Unique Ingredient Identifier: MAT637500A

Background: Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication: Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1

Completed

Conditions: Male Breast Carcinoma
Stage IIIA Breast Cancer
Adult Solid Neoplasm
Inflammatory Breast Carcinoma
Stage IIIB Breast Cancer

Interventions: Drug: Capecitabine
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tipifarnib

First Posted Date: 2003-10-07

Last Posted Date: 2015-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT00070252

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Wisconsin Medical School, Milwaukee, Wisconsin, United States

and more 4 locations

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Previously Treated Myelodysplastic Syndromes
Refractory Anemia
Refractory Anemia With Excess Blasts
Refractory Cytopenia With Multilineage Dysplasia
Refractory Anemia With Excess Blasts in Transformation
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Refractory Anemia With Ringed Sideroblasts

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-08-29

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT00005845

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-07-15

Last Posted Date: 2012-06-28

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 22

Registration Number: NCT00003707

Locations: 🇺🇸
San Antonio Cancer Institute, San Antonio, Texas, United States

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00060125

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: tipifarnib
Radiation: radiation therapy

First Posted Date: 2003-04-09

Last Posted Date: 2013-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00058097

Locations: 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: tipifarnib
Drug: cisplatin
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-03-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00055757

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2012-06-29

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Registration Number: NCT00054470

Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase 1

Completed

Conditions: Adult Glioblastoma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma

Interventions: Drug: tipifarnib
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00049387

Locations: 🇺🇸
Adult Brain Tumor Consortium, Baltimore, Maryland, United States

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 2

Completed

Conditions: Juvenile Myelomonocytic Leukemia

Interventions: Drug: tipifarnib
Drug: isotretinoin
Drug: fludarabine phosphate
Drug: cytarabine
Radiation: radiation therapy
Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Procedure: allogeneic bone marrow transplantation
Procedure: double-unit umbilical cord blood transplantation
Procedure: umbilical cord blood transplantation
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00025038

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 125

Registration Number: NCT00027872

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy